← All trials
NCT05861895
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2023
- Primary completion
- Apr 23, 2025
- Completion date
- Dec 22, 2025
- First posted
- May 17, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 84
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HighField Biopharmaceuticals CorporationLead sponsor
- Mary Crowley Cancer CenterOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.